Peptide questions · Retatrutide
How long does retatrutide take to work?
Reviewed Evidence: EstablishedPublished by PepVault
Retatrutide’s onset is days–2 weeks, its peak effect comes at 48+ weeks, and its typical duration is ongoing, by the library’s timeline (backed by moderate evidence).
The timeline’s basis: Phase 2 trial data (NEJM 2023), phase 3 trials (TRIUMPH-1, NEJM 2026; TRIUMPH-2, The Lancet 2026) and Lilly's phase 3 toplines. Not yet FDA-approved.
Retatrutide week by week
The library places seven of its research notes on retatrutide on the days they cover, from day 1 to day 476 and on: 6 on randomized trials and 1 on clinical data.
Day 1 is the first day of a run. Each bar is one of the library’s research notes, placed on the days it covers.
| When | The note | Evidence |
|---|---|---|
| Days 1–28 (weeks 1–4) | Triple-agonist is kicking in | Randomized trial |
| Days 29–84 (weeks 5–12) | Dose-response steepens | Randomized trial |
| From day 60 on | Watch for dysesthesia at higher doses | Randomized trial |
| From day 84 on | This is a maintenance medication, not a course | Clinical data |
| Days 85–168 (weeks 13–24) | Higher steps: strong satiety | Randomized trial |
| Days 169–336 (weeks 25–48) | No plateau yet at week 48 | Randomized trial |
| Days 337–476 (weeks 49–68) | Phase 3 territory: the headline numbers | Randomized trial |

Model. Individual results vary.
The retatrutide timeline’s milestones
The library’s timeline for retatrutide marks 9 points from week 1 to week 80, backed by moderate evidence overall.
- Week 1: Triple receptor activation; commonly reported: appetite suppression even stronger than on tirzepatide
- Week 2: Commonly reported: GI side effects early on and after each dose step-up
- Week 4: First step-up: phase 3 goes from 2 to 4mg after week 4; commonly reported: appetite much lower
- Week 8: Second step-up, to 6mg in phase 3; commonly reported: GI effects settle within 1–2 weeks of each step
- Week 12: Third step-up, to 9mg in phase 3; phase 2's dose steps are all done by week 12
- Week 16: Phase 3's 12mg arm takes its last step, to 12mg; commonly reported: appetite strongly suppressed
- Week 24: ~17% loss in phase 2 at the 8 and 12mg doses
- Week 48: ~24% loss at the top phase 2 dose, still falling
- Week 80: ~25% average loss at 12mg in phase 3 (TRIUMPH-1)
The weeks are the library’s reference timeline from studies and reported use, not a promise of what any one person will notice.
Why retatrutide takes that long
Retatrutide’s half-life is about 6 days (144 hours), so one dose is about 96.9% cleared after 30 days.
On its schedule (Weekly) the doses overlap, and the level of retatrutide keeps climbing for about 24–30 days before it levels off, so the first 24–30 days run below the level the later weeks hold.
The notes on retatrutide follow the trials’ dose steps, 2mg, 4mg, 9mg and 8mg, so the later weeks also describe higher steps than the first ones; these are steps from studies, not a schedule for a person.
Retatrutide against other metabolic & GLP-1 compounds
The library holds an onset-and-peak timeline for 21 metabolic & GLP-1 compounds, retatrutide among them; 15 of the others share its onset of days–2 weeks.
| Compound | Onset | Peak effect |
|---|---|---|
| Semaglutide | Days–2 weeks | 60–68 weeks |
| Tirzepatide | Days–2 weeks | 72+ weeks |
| Retatrutide | Days–2 weeks | 48+ weeks |
| Dulaglutide | Days–2 weeks | 24–52 weeks (glucose) |
| Exenatide | First dose (after-meal glucose) | 24–30 weeks (HbA1c) |
| Setmelanotide | 1–2 weeks (hunger) | 52 weeks (BMI) |
| Orforglipron | Days–2 weeks | 72 weeks (trial endpoint) |
| Survodutide | Days–2 weeks | 76 weeks (trial endpoint) |
| Mazdutide | Days–2 weeks | 48–60 weeks |
| Pemvidutide | Days–2 weeks | 48+ weeks |
| Cagrilintide | Days–2 weeks | 26–68 weeks (trial endpoints) |
| Pramlintide | First meal (fullness, after-meal glucose) | 16–52 weeks (weight, HbA1c) |
| CagriSema | Days–2 weeks | 68+ weeks |
| Eloralintide | Days–2 weeks | 48 weeks (phase 2 endpoint) |
| Petrelintide | Days–2 weeks | 42 weeks (phase 2, still falling) |
| Amycretin | Days–2 weeks | 36 weeks (longest trial so far) |
| VK2735 | Days–2 weeks | 78 weeks (phase 3 endpoint, not yet read out) |
| Enicepatide | Days–2 weeks | 48 weeks (phase 2 endpoint, no plateau) |
| Ecnoglutide | Days–2 weeks | 48 weeks (phase 3, no plateau) |
| Efinopegdutide | Weeks | 24–52 weeks (trial endpoints) |
| SLU-PP-332 | Unknown in people | Unknown in people |
Questions people ask
How long does retatrutide take to work?
Retatrutide’s onset is days–2 weeks, its peak effect comes at 48+ weeks, and its typical duration is ongoing, by the library’s timeline (backed by moderate evidence).
When does retatrutide reach its peak effect?
By the library’s timeline, retatrutide’s peak effect comes at 48+ weeks, backed by moderate evidence.
How long is retatrutide usually run?
The library’s timeline gives retatrutide’s typical duration as ongoing; its cycle note says: Phase 3 trials use continuous dosing.
What does the library say about the first days on retatrutide?
Its first note on retatrutide, for days 1–28 (weeks 1–4), is “Triple-agonist is kicking in”, resting on randomized trials.